Can antiviral drugs contain pandemic influenza transmission?

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Becker, Niels G ^a   Wang, Dingcheng ^a  

^a The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE;

ARTICLE; DRUG EFFICACY; DRUG UTILIZATION; EARLY INTERVENTION; EPIDEMIC; FAMILY SIZE; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HUMAN; INCIDENCE; INFECTION CONTROL; INFLUENZA VIRUS; MATHEMATICAL MODEL; PANDEMIC INFLUENZA; PROCESS MODEL; THERAPY DELAY; VIRUS TRANSMISSION; BASIC REPRODUCTION NUMBER; BIOLOGICAL MODEL; DISEASE TRANSMISSION; DOSE RESPONSE; INFLUENZA; PANDEMIC; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BASIC REPRODUCTION NUMBER; DOSE-RESPONSE RELATIONSHIP, DRUG; FAMILY CHARACTERISTICS; HUMANS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PANDEMICS; TREATMENT OUTCOME;

EID: 79953157490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017764     Document Type: Article

References (31)

1. Cheng MH, (2005) Flu, what flu. Lancet Infect Dis 5: 746.
2. Lett D, (2005) Feds to stockpile antivirals as pandemic "speed bump". Can Med Assoc J 172: 1167.
3. Esveld M, (2006) Influenza as an issue on the agenda of policy makers and government representatives. What can we do? What do we need? Vaccine 24: 6793-6795.
4. Harrod ME, Emery S, Dwyer DE, (2006) Antivirals in the management of an influenza pandemic. Med J Aust 185: S58-S61.
5. Hayden FG, Treanor JJ, Betts RF, Lobo, M Esinhart JD, et al. (1996) Safety and efficacy of the neuraminidase inhibitor gg167 in experimental human influenza. JAMA 275: 295-299.
6. Hayden FG, Treanor JJ, Fritza RS, Lobo M, Betts RF, et al. (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282: 1240-1246.
7. Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, et al. (2004) Management of influenza in households: a prospective, randomized comparison of Oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189: 440-449.
8. Moscona A, (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363-1373.
9. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, et al. (2001) Effectiveness of oseltamivir in preventing influenza in household contacts. JAMA 285: 748-754.
10. Hayden FG et al, (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 337: 874-880.
11. Nicholson KG, Aoki FY, Osterhaus A, Trottier S, Carewicz O, et al. (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355: 1845-1850.
12. Treanor JJ, et al. (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. J Am Med Assoc 283: 1016-1024.
13. Jefferson T, Demicheli V, Rivetti D, Jones M, Pietrantonj CD, et al. (2006) Antivirals for influenza in healthy adults: systematic review. Lancet 367: 303-313.
14. Jefferson T, Jones M, Doshi P, Del Mar C, (2009) Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 339: b5106.
15. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, et al. (2005) Strategies for containing an emerging influenza pandemic in southeast Asia. Nature 437: 209-214.
16. Longini IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, et al. (2005) Containing pandemic influenza at the source. Science 309: 1083-1087.
17. Barnes B, Glass K, (2007) The role of health care workers and antiviral drugs in the control of pandemic influenza. Math Biosci 209: 403-416.
18. McCaw JM, McVernon J, (2007) Prophylaxis or treatment? Optimal use of an antiviral stockpile during an influenza pandemic. Math Biosci 209: 336-360.
19. Cowling BJ, Lau MS, Ho LM, Chuang SK, Tsang T, et al. (2010) The effective reproduction number of pandemic influenza: prospective estimation. Epidemiology 21: 842-846.
20. Mercer GN, Glass K, Becker NG, (2010) Effective reproduction numbers are commonly overestimated early in a disease outbreak. Statist Med in press.
21. Caley P, Philp DJ, McCracken K, (2008) Quantifying social distancing arising from pandemic influenza. J R Soc Interface 5: 631-639.
22. Bartoszynsm R, (1972) On a certain model of an epidemic. Applications of Mathematics 13: 139-151.
23. Becker NG, Dietz K, (1995) The effect of the household distribution on transmission and control of highly infectious diseases. Math Biosci 127: 207-219.
24. Ball F, Lyne O, (2006) Optimal vaccination schemes for epidemics among a population of households, with application to variola minor in Brazil. Statist Meth Med Research 15: 481-497.
25. Glass K, Becker NG, (2009) Estimating antiviral effectiveness against pandemic influenza using household data. J Roy Soc Interface 6: 695-703.
26. Bailey NTJ, (1975) The mathematical theory of infectious diseases and its applications. London, UK Griffin.
27. Becker NG, (1989) Analysis of Infectious Disease Data. London, UK Chapman and Hall.
28. Alexander RA, Govern DM, (1994) A new and simpler approximation for ANOVA under variance heterogeneity. J Educational Statist 19: 91-101.
29. Schneider PJ, Penfield DA, (1997) Alexander and Govern's Approximation: Providing an Alternative to ANOVA under Variance Heterogeneity. J Experimental Education 65: 271-286.
30. Becker NG, Wang D, Clements M, (2010) Type and quantity of data needed for an early estimate of transmissibility when an infectious disease emerges. Euro Surveill 15: pii = 19603.
31. Mercer GN, Glass K, Becker NG, (2011) Effective reproduction numbers are commonly overestimated early in a disease outbreak. Statist Med in press, DOI: 10.1002/sim.4174.